Date: 17 Nov 2012
Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Previous investigators have suggested the existence of distinct cognitive phenotypes of Alzheimer’s disease (AD): a dysexecutive subgroup with executive functioning worse than memory and an amnesic subgroup with memory worse than executive functioning. We evaluated data from the AD Neuroimaging Initiative. We assigned people with AD to dysexecutive and amnesic subgroups using single indicators, and analogously using the ADNI-Mem and ADNI-EF composite scores developed using modern psychometric approaches. We evaluated associations between subgroup membership, APOE genotype, and single nucleotide polymorphisms (SNPs) are associated with AD, and brain vascular disease defined as white matter hyperintensities (WMH) and MRI-identified infarcts. We hypothesized that APOE ε4 and alleles associated with higher risk for AD would predict amnesic subgroup membership; alleles associated with higher WMH or infarct burden would predict dysexecutive subgroup membership. Classification agreement between the two approaches was only fair (kappa = 0.23). There was no relationship between APOE alleles and the dysexecutive or amnesic phenotypes defined by either categorization approach. There were 58 AD-related and 25 WMH- or infarct-related SNPs for which odds ratios were > 1.5 or < 0.67 for dysexecutive vs. amnesic subgroup defined by either categorization approach. Higher proportions of SNPs had odds ratios in the hypothesized direction for the subgroups defined by the modern psychometric approach for AD-related (58 % vs. 38 %, p-value < 0.001) and brain vascular disease-related SNPs (48 vs. 32 %, p-value = 0.01). Genetic variation may underlie differential performance in memory and executive functioning among people with AD. Modern psychometric composite scores produced group assignments with more SNP associations in the hypothesized direction.
Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
American Psychiatric Association. Task Force on DSM-IV. (1994). Diagnostic and statistical manual of mental disorders: DSM-IV (4th ed.). Washington, DC: American Psychiatric Association.
Cappa, A., Calcagni, M. L., Villa, G., Giordano, A., Marra, C., De Rossi, G., et al. (2001). Brain perfusion abnormalities in Alzheimer’s disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment. [Comparative Study]. Journal of Neurology, Neurosurgery, and Psychiatry, 70(1), 22–27.PubMedCrossRef
Carmichael, O., Schwarz, C., Drucker, D., Fletcher, E., Harvey, D., Beckett, L., et al. (2010). Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Archives of Neurology, 67(11), 1370–1378. doi:10.1001/archneurol.2010.284.PubMedCrossRef
Crane, P. K., Carle, A., Gibbons, L. E., Insel, P., Mackin, R. S., Gross, A., et al. (2012). Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior. doi:10.1007/s11682-012-9186-z.
Crane, P. K., Narasimhalu, K., Gibbons, L. E., Pedraza, O., Mehta, K. M., Tang, Y., et al. (2008). Composite scores for executive function items: demographic heterogeneity and relationships with quantitative magnetic resonance imaging. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of the International Neuropsychological Society: JINS, 14(5), 746–759. doi:10.1017/S1355617708081162.PubMedCrossRef
Desikan, R. S., Segonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., et al. (2006). An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. NeuroImage, 31(3), 968–980. doi:10.1016/j.neuroimage.2006.01.021.PubMedCrossRef
Galton, C. J., Patterson, K., Xuereb, J. H., & Hodges, J. R. (2000). Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. [Research Support, Non-U.S. Gov’t]. Brain: a Journal of Neurology, 123 Pt 3, 484–498.CrossRef
Gibbons, L. E., Carle, A. C., Mackin, R. S., Harvey, D., Mukherjee, S., Insel, P., et al. (2012). A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior. doi:10.1007/s11682-012-9176-1.
Goodglass, H., & Kaplan, D. (1983). The assessment of aphasia and related disorders (2nd ed.). Philadelphia: Lea & Febiger.
Jack, C. R., Jr., Knopman, D. S., Jagust, W. J., Shaw L. M., Aisen P. S., Weiner M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurology, 9(1), 119–128.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34(7), 939–944.PubMedCrossRef
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., et al. (1997). Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11(Suppl 2), S13–S21.PubMedCrossRef
Naj, A. C., Jun, G., Beecham, G. W., Wang, L. S., Vardarajan, B. N., Buros, J., et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet.
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Journal of Neuropathology and Experimental Neurology, 71(5), 362–381. doi:10.1097/NEN.0b013e31825018f7.PubMedCrossRef
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009). Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Journal of Neuropathology and Experimental Neurology, 68(1), 1–14. doi:10.1097/NEN.0b013e3181919a48.PubMedCrossRef
Potkin, S. G., Guffanti, G., Lakatos, A., Turner, J. A., Kruggel, F., Fallon, J. H., et al. (2009). Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PloS One, 4(8), e6501. doi:10.1371/journal.pone.0006501.PubMedCrossRef
Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8, 271–276.
Rey, A. (1964). L’examen clinique en psychologie. Paris: Presses Universitaires de France.
Sanchez-Cubillo, I., Perianez, J. A., Adrover-Roig, D., Rodriguez-Sanchez, J. M., Rios-Lago, M., Tirapu, J., et al. (2009). Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. Journal of the International Neuropsychological Society: JINS, 15(3), 438–450. doi:10.1017/S1355617709090626.PubMedCrossRef
Saykin, A. J., Shen, L., Foroud, T. M., Potkin, S. G., Swaminathan, S., Kim, S., et al. (2010). Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer’s & Dementia, 6(3), 265–273. doi:10.1016/j.jalz.2010.03.013.CrossRef
Storey, E., Slavin, M. J., & Kinsella, G. J. (2002). Patterns of cognitive impairment in Alzheimer’s disease: assessment and differential diagnosis. [Review]. Frontiers in Bioscience: a Journal and Virtual Library, 7, e155–e184.CrossRef
Weiner, M. W., Aisen, P. S., Jack, C. R., Jr., Jagust, W. J., Trojanowski, J. Q., Shaw, L., et al. (2010). The Alzheimer’s disease neuroimaging initiative: progress report and future plans. [Historical Article Research Support, Non-U.S. Gov’t Review]. Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association, 6(3), 202–211. doi:10.1016/j.jalz.2010.03.007. e207.CrossRef
Wechsler, D. (1981). Wechsler adult intelligence scale-revised. NY: Psychological Corporation.
Wechsler, D. (1987). WMS-R: Wechsler memory scale—revised manual. NY: Psychological Corporation / HBJ.
- Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI
Brain Imaging and Behavior
Volume 6, Issue 4 , pp 649-660
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Executive functioning
- Alzheimer’s disease
- Genetic analyses
- Author Affiliations
- 1. Department of Medicine, University of Washington, Seattle, WA, USA
- 6. Box 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA
- 2. Department of Psychiatry and Behavioral Science, University of Washington, Seattle, WA, USA
- 3. VA Puget Sound Health Care System, Seattle, WA, USA
- 4. Center for Imaging of Neurodegenerative Diseases (CIND), San Francisco VA Medical Center, San Francisco, CA, USA
- 5. Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA